Author

Elyssa N. Denault

Observed names: Denault, Elyssa, Elyssa Denault, Elyssa N Denault

Institutions: Harvard University, Massachusetts General Hospital

Observed institutions: Harvard University, Massachusetts General Hospital

ORCID: 0009-0003-7788-0827

Observed ORCID: 0009-0003-7788-0827

OpenAlex ID: A5043994611

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

2021 · James T. Coates, Sheng Sun, et al. · Cancer Discovery · 249

PDF

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

2023 · Martin S. Taylor, Connie Wu, et al. · Cancer Discovery · 92

PDF

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

2022 · Vivek Naranbhai, Kerri J. St. Denis, et al. · Cancer Cell · 36

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

2022 · Andrew A. Davis, Lorenzo Gerratana, et al. · EBioMedicine · 17

PDF

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

2025 · Laura M. Spring, Lauren Scarpetti, et al. · npj Breast Cancer · 11

PDF

Circulating Tumor DNA in Breast Cancer: Current and Future Applications

2023 · Arielle J. Medford, Elyssa N. Denault, et al. · Clinical Breast Cancer · 8

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2023 · Whitney L. Hensing, Lorenzo Gerratana, et al. · Clinical Cancer Research · 7

Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses

2021 · Siang-Boon Koh, Brian N. Dontchos, et al. · npj Precision Oncology · 7

PDF

Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration

2023 · Laura M. Spring, Lindsey Mortensen, et al. · JCO Oncology Practice · 6

Abstract OT3-15-01: TBCRC-053: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer

2023 · Joseph J. Connolly, Laura M. Spring, et al. · Cancer Research · 5

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

2022 · Elyssa Denault, Erika Nakajima, et al. · Therapeutic Advances in Medical Oncology · 5

Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes

2024 · Arielle Medford, Elyssa Denault, et al. · Cancer Research · 1

Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)

2022 · Marko Velimirovic, Lorenzo Gerratana, et al. · Cancer Research · 1

Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2025 · Whitney L. Hensing, Lorenzo Gerratana, et al.

PDF

Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2025 · Whitney L. Hensing, Lorenzo Gerratana, et al.

PDF

Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2025 · Whitney L. Hensing, Lorenzo Gerratana, et al.

PDF

Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2025 · Whitney L. Hensing, Lorenzo Gerratana, et al.

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

2025 · Whitney L. Hensing, Lorenzo Gerratana, et al.

Abstract 2024: Circulating tumor DNA detectability and targetability in patients undergoing neoadjuvant therapy for localized breast cancer

2025 · Arielle J. Medford, Elyssa Denault, et al. · Cancer Research

Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer